Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:43:32 2026-03-11 EDT			5-day change	1st Jan Change
19.96 ^USD	+2.07%		+9.52%	-10.03%

06:46am	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT
03-10	Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Evolution of the Average Target: Legend Biotech Corporation

Evolution of the Target Price: Legend Biotech Corporation

Changes in Analyst Recommendations: Legend Biotech Corporation

6f34b95da32e18caedeb1.tCYjy_Kb_Hb_Ol8SFBRv5AP37ZASh_5pdx-OuRbA3zY.jX8UrZ2tkwOpW2cjbUUelUComeEm6o8CR0Xs-l2ogA6GS2S9tt6MKcpxDg~871ce5dd0deccde15df6903316ed1e68

Analysts' recommendations: Legend Biotech Corporation

06:46am	RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating	MT
02-12	Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade	MT
02-12	Rothschild & Co Redburn Downgrades Legend Biotech to Neutral From Buy	MT
01-22	TD Cowen Downgrades Legend Biotech to Hold From Buy, Adjusts Price Target to $21 From $62	MT
01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT
01-07	Oppenheimer Initiates Legend Biotech at Outperform With $75 Price Target	MT
12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT
11-13	Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating	MT
25-10-08	RBC Trims Price Target on Legend Biotech to $75 From $77, Keeps Outperform Rating	MT
25-08-12	RBC Capital Adjusts Price Target on Legend Biotech to $77 From $75, Maintains Outperform Rating	MT
25-07-07	RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	MT
25-07-03	UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	MT
25-05-14	Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	MT
25-01-07	RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	MT
24-12-09	UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	MT
24-10-08	Redburn Initiates Legend Biotech at Buy With $86 Price Target	MT
24-07-15	TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	MT
24-06-17	Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	MT
24-05-24	HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	MT
24-05-24	Deutsche Bank Starts Legend Biotech With Buy Rating	MT
24-05-14	HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	MT
24-05-14	RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	MT
24-04-17	Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LEGEND BIOTECH CORPORATION					+198.59%
	ARGENX SE					+31.06%
	WUXI APPTEC CO., LTD.					+41.4%
	INSMED INCORPORATED					+47.74%
	BIONTECH SE					+61.94%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.9%
	GENMAB A/S					+24.6%
	AKESO, INC.					+51.67%
	SUMMIT THERAPEUTICS INC.					+92.22%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+29.82%
	Average					+60.29%
	Weighted average by Cap.					+44.80%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.56USD

Average target price

58.34USD

Spread / Average Target

+198.27%

High Price Target

86.00USD

Spread / Highest target

+339.67%

Low Price Target

21.00USD

Spread / Lowest Target

+7.36%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
TD Cowen
RBC Capital Markets
Oppenheimer
UBS
Truist Securities
Redburn Atlantic
HC Wainwright
Deutsche Bank Securities
Scotiabank
Cantor Fitzgerald
Raymond James
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim